Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) CEO Jennifer Jarrett Purchases 12,500 Shares of Company Stock

Key Points

• CEO Jennifer Jarrett purchased 12,500 shares of DMRA at an average price of $20.23, investing $252,875 and increasing her holdings by 2.5% to 512,500 shares.
• DMRA recently reported quarterly EPS of -$0.39, beating analysts’ consensus estimate of -$0.45, although analysts expect a full-year loss of approximately $2.06 per share.
• Analyst sentiment is broadly positive, with a consensus “Buy” rating and an average price target of $46.50; institutional investors own 14.2% of the company.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) CEO Jennifer Jarrett bought 12,500 shares of the business's stock in a transaction dated Friday, September 25th. The shares were acquired at an average cost of $20.23 per share, for a total transaction of $252,875.00. Following the purchase, the chief executive officer owned 512,500 shares of the company's stock, valued at approximately $10,367,875. The trade was a 2.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA stock opened at $20.66 on Monday. Damora Therapeutics, Inc. Common Stock has a 52-week low of $3.50 and a 52-week high of $38.33. The firm has a market capitalization of $1.28 billion, a P/E ratio of -6.13 and a beta of 1.46. The stock has a 50 day moving average price of $28.43 and a 200 day moving average price of $26.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.06. As a group, sell-side analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of institutional investors have recently made changes to their positions in the company. Braidwell LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $42,146,000. Seven Fleet Capital Management LP acquired a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter valued at $7,398,000. Squarepoint Ops LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $303,000. Finally, Arizona State Retirement System bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $260,000. Hedge funds and other institutional investors own 14.20% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on DMRA shares. HC Wainwright reissued a "buy" rating and set a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Guggenheim upped their target price on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday. TD Cowen raised shares of Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a research report on Monday, August 24th. Jefferies Financial Group began coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They issued a "buy" rating and a $50.00 target price for the company. Finally, Wedbush boosted their price objective on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an "outperform" rating in a research report on Thursday, July 30th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $46.50.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.